Ok—we’re on the same wavelength vis-à-vis TMC278. I interpret GILD’s interest in running two large phase-3b trials (#msg-55725398) as a vote of non-confidence in the phase-3 data produced by JNJ. I.e., even if JNJ’s data are sufficient for TMC278 to be approved, GILD evidently doesn’t think the data are good enough to allow Btripla to be a commercial success.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.